Vps34-IN-2

Vps34-IN-2 is a novel, potent and selective inhibitor of Vps34 with IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively[1]. Vps34-IN-2 shows antiviral activity against SARS-CoV-2 (IC50 of 3.1 μM), HCoV-229E (IC50 of 0.7 μM) and HCoV-OC43[2].

Product Specifications

CAS Number

[1523404-29-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PI3K; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Vps34-IN-2.html

Purity

99.81

Solubility

DMSO : ≥ 50 mg/mL|Ethanol : 50 mg/mL (ultrasonic)

Smiles

O=C1C=C(N2[C@H](C)COCC2)N=C3N(CC(C(C)C)=O)[C@H](C(F)(F)F)CCN31

Molecular Formula

C18H25F3N4O3

Molecular Weight

402.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Pasquier B, et al. Discovery of (2S) -8-[ (3R) -3-methylmorpholin-4-yl]-1- (3-methyl-2-oxobutyl) -2- (trifluoromethyl) -3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. J Med Chem. 2015 Jan 8;58 (1) :376-400.|[2]Jim Baggen, et al. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nat Genet. 2021 Mar 8.